{"type":"trials","record":{"id":28318,"source_id":"clinicaltrials-gov","external_id":"NCT02246829","title":"Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START","brief_summary":"Aflibercept (EYLEA®) induces a rapid reduction in central retinal thickness (CRT) for patients suffering from neovascular age-related-macular degeneration.1 This early dramatic reduction in CRT is already observed through week 4. Therefore it might be not necessary to consistently perform each of the three monthly consecutive intravitreal injections of the so-called loading phase.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"University Hospital, Bordeaux","enrollment":50,"countries":["France"],"start_date":"2014-09-01","completion_date":"2015-06-01","last_update_date":"2026-09-17","source_url":"https://clinicaltrials.gov/study/NCT02246829","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"START","age_range":"50 Years","comparator":null,"organization":"University Hospital, Bordeaux","interventions":["Intravitreal injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Occurence of a Dry SD-OCT 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg — 12-week after initiatio…","Time to get a dry SD-OCT after initiation of a treatment by Aflibercept — Every 2 weeks from treatment initiation (incl…","Evolution of morphological and visual modification under Aflibercept (EYLEA®) — Every 2 weeks from treatment initiation…","Occurence of pigment epithelial detachment — Every 2 weeks from treatment initiation (inclusion) to week 12","Evolution of retinal hemorrhage if any — Every 2 weeks from treatment initiation (inclusion) to week 12","Evolution in the atrophic lesions — Every 2 weeks from treatment initiation (inclusion) to week 12","Occurence the central Retinal Thickness — Every 2 weeks from treatment initiation (inclusion) to week 12"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration of All Subtypes","Intravitreal injection"],"relevance_confidence":62,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02246829","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-09-01 to 2015-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.795Z","intervention":["Intravitreal injection"],"participants":50,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Occurence of a Dry SD-OCT 12-week after initiation of a treatment by Aflibercept (EYLEA®) 2mg — 12-week after initiatio…","Time to get a dry SD-OCT after initiation of a treatment by Aflibercept — Every 2 weeks from treatment initiation (incl…","Evolution of morphological and visual modification under Aflibercept (EYLEA®) — Every 2 weeks from treatment initiation…","Occurence of pigment epithelial detachment — Every 2 weeks from treatment initiation (inclusion) to week 12","Evolution of retinal hemorrhage if any — Every 2 weeks from treatment initiation (inclusion) to week 12","Evolution in the atrophic lesions — Every 2 weeks from treatment initiation (inclusion) to week 12","Occurence the central Retinal Thickness — Every 2 weeks from treatment initiation (inclusion) to week 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","abstract context","study type"],"relevance_score":62,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28318","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}